UnitedHealthcare GI pathogen PCR Coverage Update

Coverage Criteria for Gastrointestinal Pathogen Panels

Proven / medically necessary — up to 5-target panels

Covered when ALL of the following are met for multiplex PCR panels up to 5 targets:

Clinical context

Indications: One of: diarrhea > 7 days; diarrhea with fever, bloody or mucoid stools, severe abdominal cramping/tenderness, or signs of sepsis; suspected enteric fever with recent travel to an endemic region or exposure

Panel size: Panel includes up to 5 targets3-5 targets (CPT 87505)

Proven / medically necessary — up to 11-target panels for persistent or immunocompromised patients

Covered when ALL of the following are met for multiplex PCR panels including up to 11 targets (for persistent diarrhea):

Clinical context: Evaluation of persistent diarrhea with at least one of the following: at risk for C. difficile colitis and (diarrhea >7 days OR diarrhea with fever, bloody/mucoid stools, severe cramping/tenderness, or signs of sepsis); OR AIDS; OR on immunosuppressive medications (post‑transplant or for autoimmune disease); OR other immunosuppression and other stool diagnostics have failed to yield a pathogen

Panel size: Panel includes up to 11 targets6-11 targets (CPT 87506)

Unproven / Not medically necessary

Not covered conditions: Multiplex PCR panel testing for gastrointestinal pathogens for all other indications (i.e., not meeting above clinical criteria)

Excessive panel size: Multiplex PCR panel testing > 11 targets is unproven and not medically necessary>11 targets (e.g., CPT 87507)

Appropriate use and contextual criteria

Evidence-informed considerations for appropriate use

Recommended testing criteria: Follow IDSA clinical criteria (fever, abdominal pain, bloody stool, immunocompromised status) to select patients for multiplex panel testing to maintain high clinical yield and reduce unnecessary testing.

Supported by Clark et al. validation showing reduced testing without reduced clinical yield.

When rapid results are clinically useful: Use multiplex panels to shorten turnaround time when results will change management (e.g., timely antibiotic selection, infection isolation decisions, antimicrobial stewardship interventions).

Studies report reduced time to results and impacts on antibiotic use and isolation.

When culture is required: Obtain or perform stool culture (including enrichment for Salmonella) in parallel when culture-based susceptibility, confirmation, or public health subtyping is needed.

Parallel culture is recommended because PCR may not provide isolates needed for susceptibility/public health investigations.

Medically Necessary Indications

Covered when testing is clinically indicated per guideline-recommended scenarios

Primary coverage criteria: Fecal testing (culture or culture-independent) is recommended for patients with moderate-to-severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrhea, or for immunocompromised patients; testing for bacterial pathogens is recommended when detection may change management; viral-only panels have limited impact except in immunocompromised hosts.

Based on IDSA and ACG guidance.

Conditional/Follow-up Requirements

Restricted or conditional coverage considerations

Situations requiring caution or additional action: When culture is required for susceptibility testing or public health purposes, culture-independent positive results should prompt culture follow-up; multiplex NAATs should not be used as 'tests of cure' because they detect nonviable organisms.

Per IDSA guidance and evidence reviews.

This policy does not apply in certain states where a state-specific policy or guideline takes precedence. Refer to the state-specific guidance for coverage rules in Idaho, Kansas, Kentucky, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, Tennessee; Indiana is noted as having no separate policy. Providers and reviewers should verify and follow the applicable state-level policy when serving members in these jurisdictions.

Multiplex molecular panels should not be used as a wholesale replacement for stool culture when recovery of an isolate is required for antimicrobial susceptibility testing, subtyping, or public health investigations. The evidence and guidance note that culture-independent panels can increase pathogen detection but may produce additional false positives and do not provide isolates for susceptibility or surveillance; when culture-based testing or isolates are needed, obtain or perform culture in parallel with molecular testing.

Per IDSA guidance, routine laboratory testing is generally not indicated for uncomplicated, noninflammatory acute diarrhea and acute gastroenteritis of limited duration. Testing should be reserved for patients with clinical features suggestive of bacterial or other significant enteric infection where results would affect management.

Multiplex PCR panels that include more than 11 targets (for example, 12–25 target panels described under CPT 87507) are considered unproven and not medically necessary for indications outside the specified clinical criteria. Claims for such higher-order panels may be denied because current evidence does not demonstrate clinical utility for broad, very high–plex testing outside defined indications.

Broad, unrestricted use of multiplex gastrointestinal pathogen panels in low-yield populations — such as adult outpatients without IDSA-specified clinical features (fever, abdominal pain, bloody stool, or immunocompromised status) — is discouraged. Validation studies show low clinical yield in general outpatient populations and support following guideline-based criteria to avoid unnecessary testing and potential false positives.

Do not order multiplex GPP tests in clinical situations where additional positive results would not change patient management (for example, mild self-limited viral gastroenteritis). These assays can detect nucleic acid from viable and nonviable organisms and may identify pathogens of uncertain clinical significance; testing in contexts where results will not alter therapy, isolation, or stewardship actions is therefore of limited clinical value.

Clinical Indications Supported for Coverage

Diarrhea >7 days or diarrhea with fever, bloody/mucoid stools, severe abdominal cramping/tenderness, or signs of sepsis

Clinical trigger: Diarrhea for more than 7 days

Also covered when associated with fever, bloody/mucoid stools, severe abdominal cramping/tenderness, or signs of sepsis, or when suspected enteric fever with recent travel to an endemic region.

Acute diarrhea with clinical features suggesting infectious etiology, immunocompromised host, traveler's diarrhea where rapid ID could change management

Clinical scenarios: Acute diarrhea with clinical features suggesting infectious etiology (fever, abdominal pain, bloody stools), immunocompromised host, or traveler’s diarrhea where rapid identification could change management.

Supported by validation of IDSA criteria and studies demonstrating changes in management in inpatient and pediatric cohorts.

Suspected GI infection in SOT recipients and other immunocompromised patients

Not Covered and Unproven Uses

Multiplex PCR panels with more than 11 targets (e.g., CPT 87507 describing 12–25 targets) and use of panels for indications not meeting the policy’s specified clinical criteria are considered not covered. Coverage is limited to use consistent with the clinical scenarios defined elsewhere in this policy.

Use of multiplex panels as a substitute for conventional stool culture when isolates are required for antimicrobial susceptibility testing or public health subtyping is not covered unless culture is performed in parallel. Systematic reviews and guidance emphasize that molecular assays do not provide isolates and that parallel culture may be necessary to guide susceptibility testing and surveillance.

Routine use of multiplex gastrointestinal pathogen panels for uncomplicated, noninflammatory, self-limited acute diarrhea is not covered. IDSA guidance indicates that laboratory testing is typically unnecessary in these scenarios because results are unlikely to change management.

Billing Codes and Coding Guidance

Covered CPT Codes (3-11 targets)CPTCovered

87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.

Not medically necessary / unproven panelCPTNot Covered

87507

Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets

Covered CPT Codesmixed

Not provided

No CPT/HCPCS/ICD codes are listed in this excerpt.

Regulatory/Device Codesmixed

PCH/PCI (FDA product codes)

FDA product codes referenced for 510(k) searches of marketed GI panels

Provider Actions, Documentation, and Billing Considerations

Documentation Required

Clinical indication and management documentation

Document clinical indication and how results will inform management. Testing is appropriate only when members meet evidence-based criteria (for example, IDSA guidance: moderate-to-severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrhea, or immunocompromised status). Include symptom duration, severity, travel history, immunocompromised status, prior diagnostic testing performed, and planned changes to therapy or infection-control actions that would result from positive findings.

Document duration and character of diarrhea (e.g., >7 days, bloody, mucoid)
Document fever, abdominal tenderness/cramping, or signs of sepsis
Document immunocompromised status, recent travel, or nosocomial exposure
Document how positive or negative results will change treatment or infection-control decisions

Note

Prior authorization / plan requirements not specified in excerpt

The excerpt does not specify prior authorization or other payer-specific administrative requirements. Verify benefit coverage and any plan-specific prior authorization, lab network, or claim-submission rules before ordering.

Ordering and Documentation Requirements

Documentation Required

Ordering requirement — medical records may be requested

Medical records documentation may be requested during review to verify that policy clinical criteria were met at the time of ordering; maintain accessible records to support medical necessity determinations.

Provide clinical notes documenting symptoms, duration, and relevant risk factors if requested
Documentation supports but does not guarantee coverage

Documentation Required

Ordering requirement — order based on clinical criteria and stewardship guidance

Place orders based on the policy’s clinical criteria (e.g., IDSA recommendations) and when results are expected to inform antimicrobial therapy, infection control, or other management; stewardship programs may guide appropriate ordering.

Use IDSA criteria (fever, abdominal pain, bloody stool, immunocompromised status) to select patients
Coordinate with antimicrobial stewardship when implementation affects therapy

Definitions and Terminology

inv-30: Multiplex PCR panel definition

DefinitionA molecular assay that detects nucleic acid from multiple gastrointestinal pathogens simultaneously using real-time PCR or integrated extraction/amplification platforms.

Typical targets per panelVaries by test; policy distinguishes panels by target count (e.g., 3-5 targets, 6-11 targets, >11 targets).

Common technologiesReal-time PCR, end-point PCR with microfluidics/array technologies, and integrated cartridge-based platforms.

Coverage-relevant thresholdPanels including up to 5 targets (CPT 87505) or up to 11 targets (CPT 87506) are addressed for medical necessity; panels >11 targets are considered unproven/not medically necessary.

inv-31: Suspected enteric fever definition

Definition

Frequency Limits

inv-40: Frequency limits not specified in this portion of the policy

StatementFrequency limits are not specified in this portion of the policy.

ImplicationMedical records documentation may be requested to verify clinical criteria for coverage; absence of stated frequency limits does not guarantee coverage.

ActionVerify plan-specific benefit rules for any frequency restrictions or utilization controls before ordering.

inv-41: No frequency limits stated in these excerpts

StatementNo frequency limits are stated in these excerpts of the policy.

ContextIDSA-based testing criteria and clinical indications are emphasized rather than numeric frequency limits.

Background and Evidence Context

Acute diarrheal illnesses are caused by bacteria, viruses, protozoa, and parasites; most noninflammatory acute diarrhea is self-limited and does not require laboratory testing. Multiplex molecular assays increase pathogen detection and shorten turnaround time compared with culture, but their clinical utility is greatest when rapid organism identification will change management (for example, in persistent, severe, bloody, febrile, nosocomial, or immunocompromised patients). Studies show higher detection rates with panels but mixed impact on clinical management in low-yield outpatient populations.

Appropriate use and contextual criteria

Evidence-informed considerations for appropriate use

Clark et al. validated IDSA criteria; restricted ordering reduced testing by ~32% without reducing yield.

When rapid results are clinically useful: Use multiplex panels to shorten turnaround time when results will change management (e.g., timely antibiotic selection, isolation decisions, stewardship).

OpenPayer

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea

Coverage Criteria for Gastrointestinal Pathogen Panels

Clinical Indications Supported for Coverage

Not Covered and Unproven Uses

Billing Codes and Coding Guidance

Provider Actions, Documentation, and Billing Considerations

Ordering and Documentation Requirements

Definitions and Terminology

Frequency Limits

Background and Evidence Context